Astrazeneca Pharma I
Ticker > Company >

Astrazeneca Pharma I share price

Astrazeneca Pharma India Ltd.

NSE: ASTRAZEN BSE: 506820 SECTOR: Pharmaceuticals & Drugs  80k   320   51

8593.00
+99.10 (1.17%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 8748.1

Today's Low

₹ 8450

52 Week High

₹ 9049.95

52 Week Low

₹ 5000

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 21482.5 Cr.

Enterprise Value

₹ 20976.66 Cr.

No. of Shares

2.5 Cr.

P/E

221.54

P/B

30.25

Face Value

₹ 2

Div. Yield

0.28 %

Book Value (TTM)

₹  284.08

CASH

₹ 505.84 Cr.

DEBT

₹ 0 Cr.

Promoter Holding

75 %

EPS (TTM)

₹  38.79

Sales Growth

29.17%

ROE

24.95 %

ROCE

33.94%

Profit Growth

62.66 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Astrazeneca Pharma India Ltd.

Imdur Betaloc Seloken Ramace Plendil RHINOCORT Prostodin MERONEM XyloCaine SensorCaine Iressa Casodex CRESTOR

Index Presence

The company is present in 20 Indices.

NYMIDSML400MQ100

Nifty MidSmallcap400 Momentum Quality 100 Index
44180.65
  184.650000000001 (0.41969724520412%)

NFTSML250MOMQ100

Nifty Smallcap250 Momentum Quality 100 index
42183.85
  -163.900000000001 (-0.38703354959827%)

NFT500MOQ50

Nifty500 Multicap Momentum Quality 50 index
38217.3
  -246.849999999999 (-0.641766424059798%)

NFTSMLCAP250Q50

Nifty Smallcap250 Quality 50
24133.35
  -146.150000000001 (-0.601948145554898%)

NIFTY500

Nifty 500
21339.55
  -68.4000000000015 (-0.319507472691227%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
17677.95
  -36.1499999999978 (-0.204074720138181%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
16047.25
  -37.5499999999993 (-0.233450213866504%)

NIFTYSMALLCAP250

Nifty Smallcap 250
15104.05
  -7.60000000000036 (-0.050292324134027%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
14681
  -39.1499999999996 (-0.26596196370281%)

NFT500EQUAL

Nifty 500 Equal Weight
12677.1
  -56.1000000000004 (-0.440580529639056%)

NIFTYTOTALMCAP

Nifty Total Market index
11984.9
  -41.25 (-0.343002540297599%)

SHARIAH500

Nifty500 Shariah
6697.7
  -22.1999999999998 (-0.33036205895921%)

SMLCAP

S&P Bse Small Cap
46638.13
  -165.520000000004 (-0.353647632182541%)

BSE HC

S&P Bse Healthcare
41421.5
  -48.1900000000023 (-0.11620535383795%)

BSE500

S&P Bse 500
33579.22
  -132.389999999999 (-0.392713370853537%)

S&P MIDSMLCAP

S&P Bse MidSmallCap
11839.65
  80.6700000000001 (0.686028890260881%)

MSL400

S&P Bse 400 MidSmallCap
10772.07
  -56.7100000000009 (-0.523697036970006%)

ALLCAP

S&P Bse Allcap
9819.41
  65.5699999999997 (0.672248058200675%)

SHA500

S&P Bse 500 Shariah
8988.03
  39.6900000000005 (0.443545953774671%)

SML250

S&P Bse 250 SmallCap
6039.25
  -27.4499999999998 (-0.452470041373398%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year29.17%
3 Year16.78%
5 Year12.21%

Profit Growth

1 Year62.66%
3 Year20.07%
5 Year24.29%

ROE%

1 Year24.95%
3 Year18.62%
5 Year20.1%

ROCE %

1 Year33.94%
3 Year25.27%
5 Year28.33%

Debt/Equity

0

Price to Cash Flow

770.81

Interest Cover Ratio

183.95

CFO/PAT (5 Yr. Avg.)

0.777110532680207

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2024 75.00 0.00
Sep 2024 75.00 0.00
Jun 2024 75.00 0.00
Mar 2024 75.00 0.00
Dec 2023 75.00 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 20.0713124616659% for the Past 3 years.
  • The company has shown a good revenue growth of 16.7755591100714% for the Past 3 years.
  • Company has been maintaining healthy ROCE of 25.2666333333333% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 183.95.
  • The company has an efficient Cash Conversion Cycle of -36.1385 days.
  • Company has a healthy liquidity position with current ratio of 2.2321.
  • The company has a high promoter holding of 75%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 13.2968231868567.

 Limitations

  • The company is trading at a high PE of 221.54.
  • The company is trading at a high EV/EBITDA of 83.8764.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
Net Sales 305.79 383.2 387.52 408 440.29
Total Expenditure 290.74 333.81 349.45 355.46 363.3
Operating Profit 15.05 49.39 38.07 52.54 76.99
Other Income 9.66 8.73 8.35 8.15 7.98
Interest 0.61 0 0.11 0.34 0.33
Depreciation 3.7 3.76 3.91 9.32 9.07
Exceptional Items 0 0 -57.56 0 -33.55
Profit Before Tax 20.4 54.35 -15.16 51.03 42.02
Tax 4.6 14.88 -3.37 12.6 11.17
Profit After Tax 15.8 39.48 -11.79 38.43 30.85
Adjusted EPS (Rs) 6.32 15.79 -4.72 15.37 12.34

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 831.81 813.56 805.6 1002.97 1295.53
Total Expenditure 711.11 678.09 719.42 837.85 1111.08
Operating Profit 120.7 135.47 86.18 165.12 184.45
Other Income 12.99 12.84 14.76 26.1 34.8
Interest 1.14 1.09 0.95 0.63 1.2
Depreciation 18.58 20.13 16.95 16.26 14.94
Exceptional Items 0 0 0 -40.23 16.43
Profit Before Tax 113.97 127.09 83.04 134.1 219.54
Tax 41.76 33.79 21.44 34.81 58.03
Net Profit 72.21 93.3 61.6 99.29 161.51
Adjusted EPS (Rs.) 28.88 37.32 24.64 39.72 64.6

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 5 5 5 5 5
Total Reserves 359.44 451.17 506.39 583.69 706.92
Borrowings 0 0 0 0 0
Other N/C liabilities 44.13 44.6 73.63 68.99 97.83
Current liabilities 367.1 373.43 392.3 484.4 467.15
Total Liabilities 775.67 874.2 977.32 1142.08 1276.9
Assets
Net Block 71.53 80.96 74.49 68.86 66.68
Capital WIP 24.24 4.02 2.2 1.33 0.27
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 97.71 100.52 135.31 135.95 167.21
Other N/C Assets 0.01 0.01 0 0 0
Current Assets 582.18 688.69 765.32 935.94 1042.74
Total Assets 775.67 874.2 977.32 1142.08 1276.9
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 113.97 127.09 83.04 134.1 219.54
Adjustment 9.75 14.2 9.66 -4.8 -7.07
Changes in Assets & Liabilities -2.66 -3.95 32.89 -30.19 -128.17
Tax Paid -33.64 -32.56 -24.79 -40.82 -56.43
Operating Cash Flow 87.42 104.78 100.8 58.29 27.87
Investing Cash Flow -170.8 173.03 4.74 18.11 21.74
Financing Cash Flow -6.36 -8.97 -9.46 -24.48 -44.38
Net Cash Flow -89.74 268.84 96.08 51.92 5.23

Corporate Actions

Investors Details

PARTICULARS Dec 2023% Mar 2024% Jun 2024% Sep 2024% Dec 2024%
promoters 75.00 75.00 75.00 75.00 75.00
astrazeneca pharmaceutica... 75.00 75.00 75.00 75.00 75.00
PARTICULARS Dec 2023% Mar 2024% Jun 2024% Sep 2024% Dec 2024%
investors 25.00 25.00 25.00 25.00 25.00
icici prudential (various... - - 1.53 1.43 1.40
investor education and pr... 0.43 0.42 - - 0.42
nippon life (various sche... - - - 2.92 2.92
shivani tejas trivedi 2.43 2.43 2.40 2.40 2.40
tejas bhalchandra trivedi... 2.72 2.72 2.68 2.68 2.68
investor education and pr... - - 0.42 0.42 -
nippon life india (variou... - - 2.91 - -
minaxi bhalchandra trived... 1.84 1.84 - - -
nippon life india trustee... 2.57 2.88 - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

AstraZeneca Pharma India informs about updates 28 Mar, 4:51 PM AstraZeneca Pharma India gets nod to import, distribute Sodium Zirconium Cyclosilicate powder 6 Mar, 4:11 PM AstraZeneca Pharma India gets CDSCO’s nod to import, distribute Durvalumab solutions 4 Mar, 11:30 AM AstraZeneca Pharma India informs about appointment of senior management personnel 25 Feb, 11:51 AM Astrazeneca Pharma India informs about notice of postal ballot 24 Feb, 5:58 PM Astrazeneca Pharma I - Quaterly Results 11 Feb, 7:16 PM Astrazeneca Pharma I - Quaterly Results 11 Feb, 7:16 PM Astrazeneca Pharma India informs about trading window closure 12 Dec, 5:15 PM Astrazeneca Pharma India informs about closure of trading window 12 Dec, 1:35 PM Astrazeneca Pharma India informs about compliance certificate 9 Dec, 5:08 PM AstraZeneca Pharma India informs about disclosure 4 Dec, 11:12 AM AstraZeneca Pharma to launch Breztri Aerosphere in January 2025 19 Nov, 9:25 AM Astrazeneca Pharma I - Quaterly Results 13 Nov, 4:37 PM Astrazeneca Pharma I - Quaterly Results 13 Nov, 4:37 PM Astrazeneca Pharma I - Quaterly Results 13 Nov, 4:37 PM AstraZeneca Pharma gets nod to import Durvalumab solution 24 Sep, 9:44 AM Astrazeneca Pharma India informs about compliances-certificate 9 Sep, 5:30 PM Astrazeneca Pharma I - Quaterly Results 8 Aug, 2:49 PM Astrazeneca Pharma I - Quaterly Results 8 Aug, 2:49 PM Astrazeneca Pharma I - Quaterly Results 8 Aug, 2:49 PM Astrazeneca Pharma India informs about AGM 16 Jul, 4:58 PM Astrazeneca Pharma India informs about disclosure 3 Jul, 2:30 PM AstraZeneca Pharma India informs about disclosure 21 Jun, 5:10 PM AstraZeneca Pharma India informs about appointment of senior management personnel 1 Jun, 10:16 AM Astrazeneca Pharma I - Quaterly Results 27 May, 5:40 PM Astrazeneca Pharma I - Quaterly Results 27 May, 5:40 PM Astrazeneca Pharma I - Quaterly Results 27 May, 5:40 PM AstraZeneca Pharma India informs about certificate 3 May, 5:25 PM AstraZeneca Pharma India informs about certificate 3 May, 5:21 PM AstraZeneca Pharma gets nod to import for sale, distribution of Trastuzumab deruxtecan lyophilized powder 27 Mar, 12:00 PM AstraZeneca Pharma India, Mankind Pharma enter into agreement 11 Mar, 5:15 PM Astrazeneca Pharma India informs about press release 11 Mar, 4:58 PM AstraZeneca Pharma India informs about change in role of senior management personnel 20 Feb, 10:47 AM Astrazeneca Pharma I - Quaterly Results 8 Feb, 6:17 PM Astrazeneca Pharma I - Quaterly Results 8 Feb, 6:17 PM Astrazeneca Pharma I - Quaterly Results 8 Feb, 6:17 PM AstraZeneca Pharma gets nod to import pharmaceutical formulations of new drug for sale 20 Jan, 4:59 PM Astrazeneca Pharma India informs about updates 20 Jan, 2:50 PM AstraZeneca Pharma to launch Trastuzumab deruxtecan in January 2024 21 Dec, 9:30 AM AstraZeneca Pharma India informs about closure of trading window 15 Dec, 4:56 PM AstraZeneca Pharma India informs about certificate 15 Dec, 4:48 PM AstraZeneca Pharma India gets nod to import pharmaceutical formulations of new drug 4 Dec, 10:29 AM AstraZeneca Pharma gets permission to import pharmaceutical formulations 22 Nov, 9:39 AM AstraZeneca Pharma India planning to exit manufacturing site in Bangalore 16 Nov, 4:44 PM Astrazeneca Pharma India informs about compliances-certificate 16 Nov, 1:01 PM Astrazeneca Pharma I - Quaterly Results 9 Nov, 5:10 PM Astrazeneca Pharma I - Quaterly Results 9 Nov, 5:10 PM AstraZeneca Pharma India informs about loss of share certificate 21 Oct, 2:32 PM AstraZeneca Pharma India informs about appointment of senior management personnel 15 Sep, 11:59 AM AstraZeneca Pharma India informs about closure of trading window 14 Sep, 5:01 PM

Astrazeneca Pharma I Stock Price Analysis and Quick Research Report. Is Astrazeneca Pharma I an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Astrazeneca Pharma I and its performance over the period of time. Astrazeneca Pharma I stock price today is Rs 8607.65.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Astrazeneca Pharma I cash from the operating activity was Rs 27.87 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Astrazeneca Pharma I has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Astrazeneca Pharma I , the EPS growth was 62.6649 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Astrazeneca Pharma I has OPM of 14.2374163469777 % which is a bad sign for profitability.
     
  • ROE: Astrazeneca Pharma I have a healthy ROE of 24.9484 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Astrazeneca Pharma I is Rs 8607.65. One can use valuation calculators of ticker to know if Astrazeneca Pharma I share price is undervalued or overvalued.
Last Updated on:
Brief about Astrazeneca Pharma I

AstraZeneca Pharma India Ltd. Financials: Check Share price, Balance Sheet, Annual report and Quarterly Results for company analysis

AstraZeneca Pharma India Ltd. is a leading Indian pharmaceutical company, listed on the BSE and NSE. It specializes in manufacturing, marketing, and distribution of various pharmaceuticals. Long-term investors need access to comprehensive stock analysis to make informed investment decisions. In this article, we will provide detailed analysis of AstraZeneca Pharma India Ltd.'s stock analysis page.

AstraZeneca Pharma India Ltd. Share Price:

AstraZeneca Pharma India Ltd.'s share price is a critical factor considered by long-term investors before making any investment decisions. Our stock analysis page provides users with historical share price charts, which is a valuable resource for monitoring the company's performance. Long-term investors should monitor price trends to understand the future potential of the stock. A stock's share price is determined by a range of factors such as market sentiment, financial performance, and general economic conditions. 

AstraZeneca Pharma India Ltd. Balance Sheet:

AstraZeneca Pharma India Ltd.'s balance sheet provides insights into the company's financial health and stability. A strong balance sheet instills confidence among investors, reflecting the favorable position of the company's finances. On our stock analysis page, we provide users access to AstraZeneca Pharma India Ltd.'s balance sheet as a downloadable document. By analyzing the balance sheet closely, long-term investors can understand the company's financial strength and performance.

AstraZeneca Pharma India Ltd. Annual Report:

AstraZeneca Pharma India Ltd.'s annual report contains critical information for long-term investors regarding the company's strategic initiatives and financial performance. Our website offers access to downloadable copies of AstraZeneca Pharma India Ltd.'s annual reports, which investors can use for in-depth analysis of the company's performance. Understanding the annual report is essential for long-term investors since it provides insights into the company's future growth trajectory.

AstraZeneca Pharma India Ltd. Dividend:

AstraZeneca Pharma India Ltd.'s dividend payout policy is an essential factor that long-term investors consider when assessing the stock's potential. Dividends are an investor's primary source of passive income, and their stability over the years can instill investor confidence in the company. Our website features insight into AstraZeneca Pharma India Ltd.'s dividend payout trends, which assisted long-term investors in analyzing the stock's viability as a long-term investment option.

AstraZeneca Pharma India Ltd. Quarterly Results:

Investors require up-to-date information on the company's financial performance, which is available through AstraZeneca Pharma India Ltd.'s quarterly results. The reports contain important information about the company's operations, including revenue, profits, and losses, providing as a crucial tool for long-term investors. Our website provides a downloadable copy of the company's quarterly results for informed analysis of the company's financial health to enable long-term investment decisions.

AstraZeneca Pharma India Ltd. Stock Price:

Monitoring AstraZeneca Pharma India Ltd.'s stock prices is a crucial element of analyzing the company's overall performance accurately. Our stock analysis page features current stock price updates, which investors can access to assess market trends and potential investment opportunities. These updates are valuable resources that investors can use to evaluate the stock's performance and make informed investment decisions. Our website provides pre-built screening tools to help investors analyze stock price and performance.

AstraZeneca Pharma India Ltd. Price Chart:

Our website provides a price chart that allows investors to visualize AstraZeneca Pharma India Ltd.'s share price trends over a specific period, making historical comparisons. This chart is an essential tool for long-term investors to track the company's performance over time, and make informed investment decisions.

AstraZeneca Pharma India Ltd. News:

Our website provides users timely news articles related to the company for up-to-date information. News can impact stock prices, which makes staying updated imperative for long-term investors. The news section of our website offers reliable information on important events, regulatory changes, and other factors that can affect the stock's performance.

AstraZeneca Pharma India Ltd. Concall Transcripts:

AstraZeneca Pharma India Ltd. conducts conference calls with investors and analysts to discuss and provide updates on the company's quarterly financial results. These concall transcripts provide investors with insights into the company's future guidance and outlook. Ticker website provides access to these critical documents, allowing long-term investors to stay informed on the company's financial health and future growth.

AstraZeneca Pharma India Ltd. Investor Presentations:

AstraZeneca Pharma India Ltd. prepares investor presentations to provide investors with detailed information on the company's operations and performance. These presentations serve as critical resources for long-term investors to study the company's strategic initiatives, providing necessary insights that can impact the stock's value. Our website offers access to these presentations, which investors can download for in-depth analysis.

AstraZeneca Pharma India Ltd. Promoters and Shareholders:

AstraZeneca Pharma India Ltd.'s promoters significantly influence the company, and their background and affiliations are essential elements of stock analysis. Our stock analysis page features important information about the company's promoters and other shareholders. Long-term investors need to consider these elements before making informed investment decisions.

AstraZeneca Pharma India Ltd. Pre-built Screening Tools:

Investors can use ticker's pre-built screening tools to analyze AstraZeneca Pharma India Ltd.'s stock based on specific criteria. These tools assist investors in making informed investment decisions, indicating how the stock is performing against other stocks in the same industry.

AstraZeneca Pharma India Ltd. Premium Feature Tools:

Our website provides premium feature tools such as DCF Analysis, BVPS Analysis, Earnings Multiple Approach, and DuPont Analysis, for long-term investors to analyze AstraZeneca Pharma India Ltd.'s stocks in-depth. These tools are crucial in assessing the stock's future potential and enabling investors to make informed long-term investment decisions.

AstraZeneca Pharma India Ltd. Annual Reports and Quarterly Results:

Access to AstraZeneca Pharma India Ltd.'s annual reports and quarterly results is critical in analyzing the company's future potential. Our website provides these documents for download, which investors can use to analyze the performance of the company's operations and evaluate its financial health.

In summary, AstraZeneca Pharma India Ltd. is a remarkable Indian pharmaceutical company that specializes in the manufacturing and marketing of various pharmaceuticals, making it an option for long-term investors. Our website provides various stock analysis tools, including share price, balance sheet, annual report, dividend, quarterly result, stock price, price chart, news, concall transcripts, investor presentations, promoters, and shareholders. Pre-built screening tools and premium feature tools such as DCF Analysis, BVPS Analysis, Earnings Multiple Approach, and DuPont Analysis, along with access to annual reports and quarterly results as downloadable documents, make our website a one-stop-shop for long-term investors looking for comprehensive stock analysis. 

AstraZeneca Pharma India Balance Sheet Analysis

AstraZeneca Pharma India has demonstrated a continuous growth in its financial health from March 2020 to March 2024, as per the latest data from the company's standalone balance sheet. A keen observation of the figures reveals several insightful trends about the company's financial direction.

AstraZeneca Pharma India's Growth in Reserves

The total reserves of AstraZeneca Pharma India have shown a healthy increase from Rs. 359.44 Cr. in March 2020 to Rs. 706.92 Cr. in March 2024. This consistent upward trajectory in reserves underscores the company's ability to retain earnings and potentially reinvest in business expansion and development.

AstraZeneca Pharma India's Liabilities and Debt Management

Interestingly, AstraZeneca Pharma India has maintained its borrowings at zero throughout the observed period, indicating a robust financial structure that relies less on debt for operations or expansion. The total liabilities have seen a steady rise from Rs. 775.67 Cr. in March 2020 to Rs. 1,276.90 Cr. in March 2024, mainly due to an increase in current liabilities and other non-current liabilities, suggesting a managed growth in operational scale.

AstraZeneca Pharma India's Asset Growth

The total assets of AstraZeneca Pharma India have matched the growth in liabilities, ensuring a balanced financial statement over the years. From Rs. 775.67 Cr. in March 2020, the total assets have grown to Rs. 1,276.90 Cr. by March 2024, with a noteworthy increase in current assets, from Rs. 582.18 Cr. to Rs. 1,042.74 Cr., reflecting an expansion in liquidity and operational assets.

This analysis is based on the Standalone Balance sheet of AstraZeneca Pharma India. Investors monitoring this stock might also delve into market trends and the pharmaceutical sector's performance on major indices like NSE and BSE for a broader market perspective.

Read More
X